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PERSPECTIVES IN CLINICAL NEPHROLOGY
Chronic viral hepatitis and the management of chronic
renal failure
Hepatitis B
The hepatitis B virus (HBV) is a double-stranded DNA virus [1]
which is generally spread by intimate contact or percutaneously in
infected blood via contaminated needles or tubing. In typical
acute hepatitis B, hepatitis B surface antigen (HBsAg) is the first
marker of infection detectable in serum [2]. By the time the
patient develops symptoms of acute hepatitis, after an incubation
period of up to 140 days, other markers of HBV infection are
present in serum, including antibody to the hepatitis B core
antigen (anti-HBc). [In contrast, free hepatitis B core antigen
(HBcAg), a marker of viral replication found in hepatocytes, does
not circulate in serum.] Initially, anti-HBc is predominantly an
1gM antibody that persists for about six months and serves as a
marker of acute or recent hepatitis B. Subsequently, only IgG
class anti-HBc persists and serves as a marker of previous acute
hepatitis B. With resolution of acute hepatitis B, protective
antibody directed against HBsAg (anti-HB5) appears, signifying
immunity against HBV. Additional HBV-related viral products
detectable in serum by routine testing include HBV DNA and
hepatitis B e antigen (HBeAg), both of which indicate active viral
replication and generally disappear with resolution of acute
hepatitis B [2].
Only a minority of infected immunocompetent adults fail to
recover from acute hepatitis B and develop chronic hepatitis B. In
these individuals, about 5% of acutely infected persons, HB5Ag
persists in serum and anti-HBs fails to appear. By contrast,
patients acquiring HBV infection while on chronic hemodialysis
have a much higher likelihood than immunocompetent persons of
developing chronic hepatitis B, Two phases of chronic HBV
infection can be identified. In the early months and years of
chronic HBV infection, viral replication persists and is manifested
by high levels of HBV DNA and HBeAg in serum. This "repli-
cative" phase is often accompanied by necroinflammatory
changes in the liver and elevated serum aminotransferase levels.
Because of the high viral load in their serum, patients in the
replicative phase are highly infectious to others [2]. The second
phase of chronic HBV infection is the "nonreplicative" phase,
signified in most cases by loss of HBeAg, which occurs at a rate of
10 to 15% per year in patients with chronic HBV infection and is
often heralded by a transient increase in disease activity with a rise
in aminotransferase levels. With loss of HBeAg, antibody to
HBeAg may appear in serum, HBV DNA levels fall significantly,
and liver disease activity subsides both biochemically and histo-
logically. Infectivity is much reduced once HBeAg is lost, although
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minute concentrations of HBV DNA may remain detectable by
polymerase chain reaction for variable periods of time [2].
Hepatitis B and hemodialysis
Viral hepatitis was recognized as a major problem in hemodi-
alysis units by the late 1960s in both Europe and North America
[3—5]. Between 1967 and 1971, the European Dialysis and Trans-
plant Association reported annual incidence rates for HBV
infection of 5 to 10% in patients undergoing chronic hemodialysis
[6].
Recognition of the role of HBV as a cause of hepatitis in
hemodialysis units dates back more than 20 years. Garibaldi et al
[5] reported on a prospective study of viral hepatitis in 65
hemodialysis units in the United States between 1967 and 1970.
Although testing for HB5Ag was only introduced in the latter
years of the study, the authors observed that 9 (7%) of 136
patients whose case records were extensively reviewed died of
HBV-related liver disease. A point-prevalence study of 15 dialysis
units in which 583 patients and 451 medical personnel were
screened for serologic evidence of HBV infection from 1972 to
1973 identified HBsAg in the serum of 16.8% of the patients and
2.4% of the medical staff. Antibody to HBsAg was detected in
34.0% of patients and 31.3% of staff [7]. This study also demon-
strated that serologic evidence of HBV infection was correlated
with both the number of units of blood transfused and, especially,
the length of time on chronic hemodialysis. A survey of 750
American dialysis centers undertaken by Alter and colleagues at
the Centers for Disease Control in (CDC) [8] found that, in 1976,
the overall prevalence of HBs antigenemia was 7.8% among
22,876 patients and the annual incidence rate of HBV infection
was 3.0% among 33,875 tested individuals. A repeat survey in
1980 demonstrated a significant decline in the prevalence of HBV
infection to 3.8% and in the incidence of HBV infection to 1%,
presumably because of the introduction of infection control
measures (see below).
Because of these and similar reports [9], in 1977, the CDC
issued recommendations for controlling the spread of HBV in
hemodialysis centers [10]. These recommendations included seg-
regation of HBsAg-positive patients from HBsAg-negative pa-
tients, the use of dedicated dialysis machines for HB5Ag-positive
patients, and regular serologic screening for HBsAg and anti-HBs,
in addition to routine cleaning and disinfection procedures. In a
follow-up study by Alter and colleagues from the CDC on the
impact of these recommendations on HBV infection in 1,255
hemodialysis units [11], a significant decline in HBsAg seroposi-
tivity among patients and staff was observed between 1976 and
1982. The incidence of HBsAg seropositivity in patients declined
from 3.0% in 1976 to 0.5% in 1982, and the incidence in staff
decreased from 2.6% to 0.5% during those years. Clearly, the
CDC recommendations had a considerable impact on reducing
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Table 1. HBV infection and HD patients
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Abbreviations are: HBV, hepatitis B virus; HD, hemodialysis.
the problem of HBV transmission in hemodialysis units in the
United States. Indeed, in the latest of a series of comprehensive
annual surveys of U.S. hemodialysis units by Alter and colleagues
from the CDC [121, the annual incidence of HBV infection among
patients had declined further to 0.1% in 1989, with a prevalence of
1.4%, and the annual incidence among staff members had de-
clined to 0.1%, with a prevalence of 0.3%. It is particularly
noteworthy that the major decline in the HBV infection rate
between 1976 and 1980 antedated the widespread availability of
HBV vaccination.
Improved control of the spread of HBV within hemodialysis
units has probably been less dramatic in other countries where
there is a higher prevalence of HBV in the general population. In
a study of renal transplant recipients, Degos et al noted that the
prevalence of HBV infection in hemodialysis units in France was
46.2% and 15.8%, respectively, before and after the introduction
of control measures to prevent the spread of HBV [131. In
hemodialysis units in other areas endemic for HBV, including
Israel [14] and Saudi Arabia [15], high incidence rates for HBV
infection continue to be reported.
Besides serving as a reservoir for the spread of HBV to other
patients and medical staff, patients chronically infected with HBV
are at risk of developing decompensated liver disease. A high rate
of chronicity as well as progression of liver disease have been
described in patients on HD who become infected with HBV
(Table 1). Furthermore, active viral replication promotes histo-
logical progression [16—18].
The high risk of chronicity following infection with HBV in
patients on hemodialysis has been attributed in part to depressed
cell-mediated immunity. Lee et al studied lymphoproliferative
responses in hemodialysis patents with and without HBV infec-
tion as well as HBV-infected controls without renal disease, and
observed depressed lymphoproliferative responses to phytohem-
agglutinin and concanavalin A only in the HBV-infected hemo-
dialysis patients [19]. These results suggest impairment of cell-
mediated immunity despite a normal number of T cells and an
increased CD4ICD8 ratio in all the hemodialysis patients.
Hepatitis B vaccination
With the widespread application of HBV vaccination, initially
with plasma-derived and more recently with recombinant vaccines
containing HBsAg, it has become apparent that patients on
chronic hemodialysis have a suboptimal antibody (anti-HBs)
response compared to the general population. In an early trial,
Stevens et al reported that more than 80% of 79 hemodialysis
patients developed anti-HBs following two or three doses of a
plasma-derived HBV vaccine [20]. However, Crosnier et al dem-
onstrated that the response rate and protective efficiency of
vaccination was lower in patients than staff in French hemodialysis
units [21]: only 26 of 43 (60%) hemodialysis patients developed
anti-HBs titers >10 mIU/ml (a level felt to provide protection).
Vaccine responders tended to be female and less than 50 years
old. In contrast, 93% of staff members developed protective
antibodies in this study. In addition, the level of anti-HBs was
20-fold higher in the medical staff responders than the hemodial-
ysis responders [22]. A number of host factors have been identi-
fied that contribute to nonresponse to the HBV vaccine both in
normal and dialysis patients. These include older age, obesity, and
possession of the major histocompatibility complex haplotype
HLA-B8, SCOI, DR3 [23, 24].
A variety of approaches have been tried to enhance the
response to HBV vaccination in hemodialysis patients. The yeast-
derived vaccine is not more immunogenic than the plasma-
derived vaccine, and nonresponse to one type of vaccine is
generally not overcome by vaccination with the alternative type
[25]. Kohler and colleagues demonstrated anti-HBs seroconver-
sion following a fourth dose of plasma-derived vaccine in 16 of 43
(37%) initial nonresponders; however, in nine such responders
(56%) the initial response to vaccination had actually been
transient, not absent [26]. Bruguera and colleagues, using a
yeast-derived HBV vaccine, found that a higher dose (40/j.g
rather than 20/jg) and a schedule of four injections at 0, 1, 2, and
6 months was superior to a regimen of 0, 1,2, and 12 months; both
regimens were more efficacious in producing an adequate immune
response than a three-injection schedule [27]. Inclusion in the
vaccine of a more extended portion of the HBV genome contain-
ing the pre-S2 (as well as the HBsAg) protein may increase the
response rate to vaccination in hemodialysis patients [25], and the
appearance of anti-pre-S2 antibodies in vaccinees has been shown
to correlate with high anti-HBs titers [28]. The response rate to
HBV vaccination in this population has also been reported to
increase with co-administration of immune modulators such as
gamma interferon [29] and thymopentine [30]. Use of these and
other novel approaches, such as adjuvant interleukin-2, are under
study [25, 31j.
Even following an adequate anti-HBs response to vaccination,
hemodialysis patients appear to have a poor ability to maintain
protective antibody levels. Fleming and colleagues [32] reported
that 13 of 23 (57%) vaccine responders had lost detectable
anti-HBs within six months of vaccination. In another study
anti-HBs levels of at least 10 mIU/liter developed in 44 of 60
(73%) hemodialysis patients following four doses of recombinant
hepatitis B vaccine [33], but after three years of follow-up,
anti-HBs levels were undetectable in 18 of 44 responders (41%).
Patients with persistent anti- HBs levels typically were younger and
had higher initial anti-HBs levels than those in whom anti-HBs
levels became undetectable. Of particular note, four cases of acute
hepatitis B in hemodialysis patients, despite the previous devel-
opment of apparently protective anti-HBs levels, were described
by Stevens et al [34]. Anti-HBs levels had declined by the time of
infection in three cases and may have been negated by therapeutic
immunosuppression in the fourth patient, who had undergone
renal transplantation.
Perhaps the most important reason for lack of protection by
J-IBV vaccine in hemodialysis patients is lack of application. A
national surveillance of dialysis units in the U.S., undertaken in
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Table 2. RT in patients with HBV infection
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Abbreviations are: RT, renal transplantation; HBV, hepatitis B virus.
1989, found that only 19% of susceptible patients and 55% of staff
members had been vaccinated against HBV [12]. Despite its
limitations, HBV vaccination is useful in the hemodialysis popu-
lation. Still, the recommendations of the CDC concerning control
measures against HBV in hemodialysis units have stood the test of
time and for the foreseeable future will remain the mainstay of
controlling HBV in this setting. It is possible that vaccination of
patients before the development of advanced chronic renal dis-
ease will further increase the effectiveness of measures to limit the
spread of HBV in the dialysis setting [25].
Hepatitis B and renal transplantation
The effect of renal transplantation (RT) and associated thera-
peutic immunosuppression on the course of HBV-related liver
disease has been a subject of debate in the literature for many
years [35—38]. Reports from the early 1970s suggested that HBsAg
seropositivity was associated with serious hepatic dysfunction in
transplant recipients [35, 37, 38].
In a detailed prospective study of 22 HBV-infected RT recipi-
ents, Parfrey et a! documented progression of liver disease over a
mean follow-up of 83 months [39]. Cirrhosis developed in 12 of 20
(60%) patients who did not have cirrhosis on initial biopsy. Eleven
of the 20 (55%) died of liver disease. In contrast, 10 HBV-infected
patients on chronic hemodialysis, followed over a comparable
period of time, experienced no evidence of progressive hepatic
dysfunction or death from liver disease. Of particular note was
that three of the deaths were due to primary hepatocellular
carcinoma, presumably because of the increased rate of cirrhosis
as also noted by others [40, 41] (Table 2).
The effect of RT on HBV viral activity has been described by
Dusheiko et al [42] and others [43]. Increased replication with
reappearance or increase in serum HBV DNA levels and HBeAg
occurs as well as even reappearance of serum HBsAg following
apparent clearance of previous HBV infection. Rao, Kasiske and
Anderson in Minneapolis have also emphasized the importance of
HBV infection in determining the clinical severity of liver disease
post -RT in recipients with clinical hepatic dysfunction [44]. Initial
liver biopsies showed more severe histologic liver injury in the
HBsAg-positive RT recipients in their report. Fourteen of 26
(54%) HBsAg-positive patients died of liver disease compared to
5 of 42 (12%) HBsAg-negative patients after a follow-up averag-
ing six to eight years. Serial liver biopsies demonstrated, however,
that progression to cirrhosis was common in both HBsAg-positive
(4 of 7) and HBsAg-negative patients (5 of 11). Pol and colleagues
from France, came to similar conclusions regarding the effect of
HBV on disease severity and progression [45].
On the basis of these and similar recent studies [35—45], a
number of conclusions can be made: HBV infection is associated
with significant hepatic dysfunction in many RT recipients. More-
over, RT accelerates the progression of liver disease, and at least
some HBV-infected RT recipients experience increased morbidity
and even mortality as a consequence of HBV infection. Because
of these observations, some workers have questioned the wisdom
of offering RT to HBV-infected patients. Harnett and colleagues
have provided additional information on the outcome of HBV-
infection in RT recipients compared to a group of patients on
hemodialysis [17, 46]. Thirty-one HBV-infected patients were
followed for a mean of 55 months following infection. Whereas
only one of the 12 deaths in the dialysis group could be attributed
to liver disease, 8 of 14 (57%) deaths in the RT group were related
to liver disease. The excess mortality rate in the RT group
persisted when adjusted for a longer period of follow-up in the RI'
group. On the basis of these findings, the authors cautioned
against RT in HBV-infected patients and implied that hemodial-
ysis may offer a better long-term outcome in such patients.
Friedlaender and colleagues from Israel have offered a less
gloomy view of RT in HBV-infected patients based on their
personal experience as well as a comprehensive review of the
literature [47]. They suggest that most prior reports had selected
patients who already had significant hepatic dysfunction at the
time of RT or who had acquired HBV following RT and thus
might have been expected to deteriorate due to high-dose post-
operative immunosuppression. Friedlaender also described the
severe nature of acute HBV infection occurring post-RT in 4 of
200 RT recipients [47]. Two of the 4 patients died of "acute yellow
atrophy," presumably due to HBV, one patient developed chronic
hepatic dysfunction, and one patient seroconverted to anti-HBs.
An additional patient had acute HBV infection perioperativly and
recovered with development of immunity. Others have reached
similar conclusions [48].
Immunosuppressive agents are clearly permissive for HBV
replication in RT recipients. As demonstrated by Dusheiko and
others [42, 49], RT is associated with reactivation of HBV
replication. Degos and colleagues also demonstrated viral reacti-
vation and/or increased replication in HBsAg-positive patients
post-RT [13]. In addition, they described a subset of patients
without HBsAg or HBV DNA in serum before RT but with HBV
DNA detected by dot-blot hybridization in serum following RT, a
finding which suggests that immunosuppression amplifies even
minimal residual HBV replication. In many of this subset, hepatic
tissue contained HBV DNA, particularly if there was histological
evidence of chronic hepatitis at the time of RT. More recently, the
same group has described the reappearance of HBsAg following
RT in a patient who had had acute HBV infection 10 months prior
to RT and then developed an anti-HBs response [50]. This
patient, in fact, had HBV DNA detectable in serum by PCR
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pre-RT, suggesting that resolution of acute infection had been
relative rather than absolute.
The deleterious effect of therapeutic immunosuppression on
the course of HBV infection has been recognized in a number of
other clinical settings. Reactivation of HBV infection has been
well described in HBsAg-positive patients receiving cytotoxic
cancer therapy, and has led to death from acute liver failure in
some patients [51, 52]. Analogous to RT, orthotopic liver trans-
plantation in many HBV-infected patients is associated with
reinfection of the liver graft followed by rapidly progressive liver
disease with reduced survival of both graft and patient [531
Absence in serum of hepatitis B e antigen and/or HBV DNA in
RT recipients may decrease the likelihood of hepatic decompen-
sation, but does not preclude a poor outcome due to worsening of
liver disease [54]. The advent of PCR testing has demonstrated
that even a minute viral level pre-transpiantation can be associ-
ated with HBV reinfection of the liver graft [53].
Therapeutic immunosuppression may enhance HBV replica-
tion via a number of mechanisms. The HBV genome contains a
glucocorticoid-responsive element that, when activated, may in-
crease the transcription of HBV genes. In a transgenic mouse
model of HBV, in which HBsAg is incorporated into the host
genome, HBsAg production is in fact regulated by glucocorticoids
as well as sex hormones [55]. Cyclosporine may also have direct
effects on HBV replication. The woodchuck hepatitis virus, a
member of the hepadnavirus family like human HBV, undergoes
increased replication when exposed to cyclosporine [56]; the
mechanism of enhanced viral replication is uncertain. It is likely
that impairment of host responses contributes to enhanced hep-
adnavirus replication related to therapeutic immunosuppression.
The observation has been made by Degos and colleagues that
the development of extensive liver fibrosis and ultimately cirrhosis
in RT recipients with HBV-related chronic hepatitis occurs in the
absence of extensive hepatocellular necrosis or inflammatory
changes [57]. This lack of a marked inflammatory response has
also been described in other HBV—infected immunocompromised
hosts, including orthotopic liver transplant recipients [58] and
patients with the acquired immunodeficiency syndrome [59], and
may account, at least in part, for the lack of elevated serum
aminotransferase levels often observed in RT recipients and other
immunocompromised hosts with chronic hepatitis B [60, 61].
The effect of HBV infection on graft survival following RT
remains controversial. In a study of RT recipients, London and
colleagues in Philadelphia reported that the presence of HBsAg in
serum delayed renal graft rejection, whereas anti-HBs was asso-
ciated with early graft rejection, particularly if the donor was male
[62]. In contrast, Chatterjee et al detected no discernible effect of
HBV infection or immunity on renal graft survival [36]. In an
astute analysis of the study reported by Degos and colleagues [13]
on HBV replication and reactivation following RT, Dienstag
attempted to reconcile some of these discrepancies [63]. He
observed that collectively over a two to three year period renal
graft survival was 82% in HBsAg-positive patients but only 61% in
HBsAg-negative patients. However, in those patients who were
HBsAg-negative in serum but HBV DNA-positive in hepatic
tissue, renal graft survival was intermediate at 75%. He concluded
that reported differences in the effects of HBsAg on graft survival
may have reflected the unrecognized presence of HBsAg negative!
HBV DNA-positive RT recipients in whom graft survival is
superior to that of truly HBV-negative recipients.
A number of approaches have been tried to arrest the progres-
sion of HBV infection in RT recipients. Several investigators have
reported on attempts to reduce therapeutic immunosuppression
for this purpose without convincing benefit [64, 65].
Others have reported on the introduction of cyclosporine
therapy [66, 67]. In a histologic study of liver disease in HBsAg-
positive RT recipients receiving cyclosporine over a mean fol-
low-up of 43 months, Stempel and colleagues concluded that the
liver disease was generally mild and speculated that this was the
result of the reduction in doses of azathioprine and prednisone
possible when cyclosporine was added to the immunosuppressive
regimen [68]. As discussed above, corticosteroids are recognized
to worsen HBV-related chronic liver disease [69], and attempts to
reduce the dose of prednisone following RT are probably appro-
priate.
Recombinant alpha-interferon has demonstrated efficacy in the
treatment of chronic hepatitis B in non-transplanted immunocom-
petent hosts and leads to loss of HBeAg in up to 50% of treated
patients with associated improvement in liver histology [70] and in
many responders ultimate resolution of HBV infection in the
several years following therapy [71]. However, because of the
immunomodulating effect of interferon, there is at least a theo-
retical risk that interferon may enhance graft rejection [72]. As
discussed later, use of interferon to treat HBV infection in RT
recipients is probably best reserved for controlled clinical trials
until more information about the risk/benefit ratio is available.
Recommendations regarding renal transplantation in
HBV-infected patients
Because of the effective control of HBV in hemodialysis units,
the number of HBV-infected patients undergoing evaluation for
RT will continue to decline. At present, decisions about RT in
HBV-infected patients should be based on both the severity of
liver histology and the results of testing for markers of replication
in serum, including HBV DNA and HBeAg. Nevertheless, the
absence in serum of HBV DNA or HBeAg prior to RT does not
preclude reactivation of HBV infection following RT under the
influence of immunosuppression. Studies in North America [39,
44, 46] have shown that patients with severe chronic active
hepatitis or established cirrhosis on liver biopsy are at particular
risk of hepatic decompensation following RT, and in these
individuals RT should be avoided, especially if markers of active
viral replication are present. In countries other than the US with
a higher prevalence of HBV in the general population, many
infected patients will continue to enter the dialysis and transplant
pool, and even within the United States, large-scale migration
from Southeast Asia, an area endemic for HBV, will undoubtedly
continue to present physicians with a dilemma about the wisdom
of transplanting infected patients.
Given the generally favorable outcome of many patients, chron-
ically infected with HBV, with less histologically severe liver
disease, such as chronic persistent hepatitis, RT should not be
precluded in these patients. However, all patients infected with
HBV must be cautioned that even histologically mild disease has
the potential to deteriorate under the influence of immunosup-
pression. It is hoped that future developments in antiviral therapy
will diminish the hazards of RT in patients with HBV infection
[73].
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Hepatitis D (delta hepatitis)
Hepatitis D virus (HDV), also known as the delta agent, is only
found in the presence of HBV infection. An RNA virus, HDV
requires HBV to complete its replicative cycle [74]. HDV infec-
tion may occur simultaneously with acute HBV infection (coin-
fection) or may be acquired during the course of chronic HBV
infection (superinfection). The clinical significance of HDV is its
ability to increase the severity of HBV infection; unlike HBV,
HDV is almost invariably associated with clinically important
hepatic dysfunction. In North America, HDV infection is most
commonly found among intravenous drug abusers who share
contaminated needles and syringes. Elsewhere in the world, HDV
is endemic in certain tropical and subtropical areas with high
prevalences of HBV infection.
Routine serologic diagnosis of HDV infection is currently based
on detection of circulating antibody to HDV antigen (anti-HDV)
[75]. In acute HDV infection, anti-HDV levels may be of low titer
and anti-HDV may disappear with resolution of infection. In
chronic HDV infection, anti-HDV levels are persistent and of
high titer.
Fortunately, HDV infection generally has not been a major
problem in hemodialysis and RT programs. A number of groups
specifically have reported the absence of HDV infection in
HBV-infected RT recipients [13, 39, 76, 77]. Nevertheless, HDV
infection should be considered in any patient with rapidly deteri-
orating liver disease due to HBV. Degos and colleagues in Clichy
described delta superinfection as a rare event in RT recipients
[57]. Previously, they had reported three cases of fulminant
hepatitis occurring among 300 RT recipients followed from 1972
to 1983 [78]; in two of these three cases, direct staining of liver
tissue identified delta antigen, implicating HDV infection.
Hepatitis C
The hepatitis C virus (HCV), an RNA virus [79], is the agent
responsible for most, if not all, cases of transfusion-associated
hepatitis, as well as many cases of sporadic non-A, non-B (NANB)
hepatitis occurring in individuals with no obvious parenteral
exposure to HCV. HCV infection is characterized by a high rate
of chronicity with a propensity to insidious progression to cirrhosis
and an increased risk of subsequent hepatocellular carcinoma.
Since identification of HCV was relatively recent, serologic tests
are still in evolution. First-generation tests, initially a radioimmu-
noassay and then an enzyme immunoassay, detected antibody to
C100-3, a recombinant polypeptide expressed from the portion of
the genome encoding non-structural proteins [80]. With first-
generation tests, detection of antibody to C100-3 (anti-HCV) was
delayed for up to several months after acute HCV infection and
never developed in 30 to 40% of patients with apparently resolv-
ing acute hepatitis C [81]. In addition, anti-HCV was not detect-
able by first-generation ETA in up to 20% of well-pedigreed cases
of transfusion-associated hepatitis despite the detection of HCV
RNA in serum by use of PCR [81]. Because of these limitations
and concerns about the nonspecificity of the first generation tests,
second-generation tests, which incorporate a wider selection of
HCV-related epitopes from regions of the genome encoding both
structural and nonstructural peptides, have been introduced [82].
The additional epitopes are C22-3, a nucleocapsid core protein,
and C200, a composite of C100-3 and C33, two peptides encoded
by the nonstructural region. The diagnosis of HCV infection is
now possible up to three months earlier with second-generation
testing than with first-generation testing. Moreover, the sensitivity
of confirming HCV as the cause of chronic NANB hepatitis is
enhanced by 10 to 20% [82]. At present, routine diagnosis of HCV
infection is based on second-generation anti-HCV testing. The
recombinant immunoblot assay (RIBA) which also incorporates
several HCV-related antigens has been introduced into routine
diagnostic use as a supplementary test which enhances specificity
of second-generation tests [2]. Although available experimentally,
detection of HCV RNA by PCR and detection of 1gM anti-HCV
are not yet used routinely in clinical practice. A recent report
highlights the limitations of even second generation serological
tests for HCV in patients on chronic dialysis [83]. Twenty-eight
(8.2%) of 340 patients tested with ELISA positive. However, an
additional eight patients were viremic by PCR indicating a high
false-negative rate for detection of HCV infection by serology
alone. The branched chain DNA test which allows quantitative
serum HCV RNA detection is currently undergoing clinical
assessment [84]. Although significantly less sensitive than PCR, it
is a reliable and reproducible technique to detect viremia. It
seems likely in the future that diagnosis of HCV infection will
include demonstration of viremia rather than detection of anti-
HCV antibodies alone.
Role of hepatitis C in liver disease associated with chronic
renal failure
After the introduction of diagnostic testing for HBV, it rapidly
became apparent that most liver disease in patients undergoing
HD or RT was not related to HBV. Despite the control of HBV
infection in dialysis units, hepatic dysfunction continued to occur
frequently [85, 86]. Bruguera and colleagues, reporting from
Barcelona in 1985, ascribed episodes of acute hepatitis to "NANB
hepatitis" by excluding HBV infection in 20 of 27 [74%] cases
[87]. In 14 cases (70%) NANB hepatitis became chronic. Prior to
the identification of HCV, similar conclusions about the impor-
tance of NANB hepatitis as a cause of hepatic dysfunction in RT
recipients had been reached by LaQuaglia et al reporting from
Boston in 1981 [88]. Hepatic dysfunction developed in approxi-
mately 10% of their 405 patients undergoing RT between 1970
and 1980, and in two thirds of the cases, a diagnosis of "NAN B
hepatitis" was made. Others had also made similar observations
about the importance of non-HBV related liver disease in RT
recipients [89].
Subsequently, diagnostic testing for anti-HCV by first-genera-
tion ELISA confirmed the importance of HCV infection as a
cause of hepatic dysfunction in hemodialysis populations [90—92].
Esteban et a! from Spain reported that 8 of 42 (19%) HD patients
were anti-HCV-positive [90]. Comparable rates of anti-HCV
seropositivity were reported from other centers [91, 92]. As
suggested by older studies [60, 61], chronic viremia not associated
with biochemical evidence of hepatic dysfunction is common in
this population of patients [83, 94]. As noted above [83], serolog-
ical diagnosis in this population is limited by lack of sensitivity [93,
94], although an anti-HCV seropositivity by second generation
testing is usually predictive of viremia [94].
An unresolved issue regarding HCV infection in HD units is
whether HD per se is a risk factor for transmission or whether the
high prevalence of anti-HCV seropositivity reflects acquisition of
HCV from other exposures. Zeldis et al observed that lack of a
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history of intravenous drug abuse, absence of multiple blood
transfusions, and negative serologic testing for current or previous
HBV infection were highly predictive of the absence of HCV
infection, suggesting that HD per se was not a risk factor for HCV
infection [91]. In contrast, a number of other investigators found
a correlation between the length of time on HD and the risk of
HCV infection [95—97]. Five (0.8%) of 590 patients on chronic
HD followed for one year developed de novo HCV seroconver-
sion preceded by viremia. At least one and possibly three of these
patients had no exposure to blood products for at least one year
prior to onset of HCV infection [98]. Genomic sequencing of
HCV isolates from three patients who developed anti-HCV
antibodies while on chronic HD were identical in a Swedish study
[99]. These patients were all dialyzed on the same shift but not the
same machines. This strongly suggests nosocomial spread within
the unit, as do other recent reports [100]. Further circumstantial
evidence of HD as a possible risk factor for HCV infection is the
finding of a lower prevalence of HCV seropositivity in patients
maintained on chronic peritoneal dialysis. Chan, Lok and Cheng,
reporting from Hong Kong, found in 130 RT recipients anti-HCV
seropositivity in 15.4% and 2.2% of patients who had previously
received chronic HD and PD, respectively, although the latter
group had less requirement for blood products as a potential
explanation [101]. With the marked reduction of transfusion
requirements in the HD population since the introduction of
erythropoietin, it may be possible to further address this issue in
non-transfused HD and PD patients. Screening of blood products
over the last several years for HCV infection has been reported to
also reduce the prevalence of infection in HD units, from 43.6%
to 21.2% in a French unit [102]. Four new cases of anti-HCV
seroconversion occurred over a two month period in this unit in
patients sharing the same dialysis machine implying nosocomial
spread. Chiaramonte et al described an outbreak of acute NANB
hepatitis in Italy occurring among patients undergoing HD on
dialysis machines without completely disposable dialysate circuits
[103]. Switching patients with acute hepatitis to machines with
completely disposable circuits appeared to abort the spread of
HCV within the unit, suggesting that the outbreak of hepatitis had
been facilitated by the dialysis system and again providing evi-
dence for transmission of HCV by HD.
The clinical consequences of HCV infection in HD patients are
probably more severe than originally appreciated. Studies per-
formed before the identification of HCV had indicated that
non-HBV related hepatic dysfunction was linica1ly mild in pa-
tients with chronic renal failure [104]. Caramelo arid colleagues
from Spain have more recently reported their observations in
patients on chronic HD with HCV infection [1051. Thirty-three
patients underwent liver biopsy. Twenty (60%) of the biopsies
showed evidence of injury consistent with chronic viral hepatitis,
including three cases of cirrhosis complicated by hepatocellular
carcinoma in one. Clinical and biochemical features were unable
to predict the severity of histological injury in the study. Although
HCV typically has an indolent progression, cirrhosis and primary
liver cancer are possible outcomes as this study illustrates. Biopsy
is the most accurate way to assess severity of liver injury.
Hepatitis C and renal transplantation
As in the HD population, a high frequency of NANB hepatitis
has been recognized for many years in RT recipients [88, 89].
However, the prognosis of non-HBV related liver disease in RT
recipients was thought to be better than that of HBV-related liver
disease [44]. Once diagnostic testing for HCV became available, a
number of reports confirmed that anti-HCV seropositivity was
indeed common in RT recipients.
Using the first-generation anti-C100-3 ELISA test, Roth and
colleagues from Miami retrospectively tested stored sera from 596
HBsAg-negative RT recipients and found that 180 (30%) were
anti-HCV positive at the time of transplantation [106]. Of note, at
one year follow-up the frequency of anti-HCV seropositivity had
decreased to 22%, implying that at least some of the initially
positive anti-HCV results may have been falsely positive and/or
that therapeutic immunosuppression suppressed production of
anti-HCV. Chan and colleagues from Hong Kong, reporting on
the use of PCR to detect HCV RNA in addition to anti-HCV
testing in 186 RT recipients, found HCV RNA in 22 (12%)
patients, including 4 who were negative for anti-HCV by a
second-generation anti-HCV antibody test [107]. Seventy-five
percent of their patients with a clinical diagnosis of chronic
"NANB" hepatitis had evidence of HCV infection. In this study,
loss of anti-HCV seropositivity after RT was not observed,
presumably because a second- rather than a first-generation
antibody test was used. In this as in other studies of HCV infection
in RT recipients, normal serum aminotransferase levels were
observed in many patients with HCV infection. As in the HD
population, serological diagnosis, even with second-generations
tests, fails to detect some cases of HCV infection discovered by
PCR [108].
A number of studies have addressed the impact of RT on the
course of HCV infection. This issue is complicated by the
undoubted inclusion of patients who acquired HCV post-RT via
transfusion of HCV-infected blood products before screening for
anti-HCV was available. Roth et al observed no differences in
patient and graft survival over a 10-year follow-up in anti-HCV-
positive patients with and without biochemical evidence of hepa-
titis [106]. Pol and colleagues from Paris performed liver biopsies
on 140 HBsAg-negative RT recipients either at the time of RT or
during subsequent follow-up [108]; 23.6% of the patients were
anti-HCV-positive by first-generation ELISA. Although the pres-
ence of anti-HCV was associated with histologic evidence of liver
injury in many patients, no differences in graft or patient survival
were observed in the anti-HCV positive patients compared to
anti-HCV-negative patients regardless of whether HCV was
acquired pre- or post-RT. However, given the typically insidious
progression of chronic hepatitis C over decades rather than years,
a longer follow-up may be required to exclude an increase in
mortality in HCV-infected RT recipients.
A recent study by Rao and colleagues in Minneapolis has
suggested that the severity of liver disease as assessed by biopsy
provides useful prognostic information in RT recipients [109].
After a mean follow-up of 5.7 years, approximately one-third of
the patients with early chronic active hepatitis and nearly two-
thirds with advanced chronic active hepatitis experienced clinical
deterioration with the development of cirrhosis and, in some
cases, death due to liver disease. The majority of patients with
progressive liver disease were infected with HBV, but some of the
liver-related deaths occurred in patients infected with HCV.
Moreover, serum levels of HCV RNA have been found to
increase post-RT [110]. Therefore, on the basis of the available
data, evidence of severe chronic active hepatitis or cirrhosis on
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liver biopsy should probably be a relative, if not absolute, contra-
indication to RT, irrespective of the cause of liver disease. As is
typical in patients with end-stage renal disease clinical and
biochemical parameters of liver disease appears insensitive mark-
ers of histological severity [110]. Other factors can contribute to
the severity of HCV-related liver injury. These include concomi-
tant alcohol abuse as well as infection by an HCV strain with
greater pathogenicity [111]. At least six different genotypes of
HCV exist. An increasing literature suggests that disease progres-
sion and interferon responsiveness are to a significant degree
determined by HCV genotype. Although a number of methods of
HCV genotyping have been described positive, diagnostic typing
is not routinely available. In the future, however, part of the
prognostic profile in RT candidates with HCV infection may well
include genotyping.
HCV transmission by organ donation
A number of reports have drawn attention to the apparent
transmission of HCV by organs from infected donors. Pereira
observed hepatic dysfunction attributable to HCV in 14 of 29
(48%) recipients of a variety of organs from HCV-infected donors
[112]. Although the interpretation of the data has been ques-
tioned [113], subsequent studies employing PCR to detect HCV
RNA have suggested that transmission of HCV occurs in at least
some recipients of organs from HCV seropositive donors and that
transmission is inevitable if the donor is viremic [114]. A recent
study of 70 recipients of 42 donors, HCV seropositive by second
generation testing, emphasizes the importance of viremia as a
prediction of HCV transmission by organ transplantation [1151.
Twenty-two of 47 (47%) recipients from viremic donors devel-
oped liver dysfunction whereas only 5 of 23 (22%) from anti-HCV
seropositive, serum PCR negative, donors developed liver disease.
Exclusion of viremic donors would decrease but not eliminate
HCV transmission in the setting. Although the long-term conse-
quences of infection with HCV via an infected donor organ are
unresolved [116], the use of organs from anti-HCV seropositive
donors should probably be restricted to life-threatening circum-
stances, particularly because RT recipients, unlike liver transplant
candidates, have the option of continuing chronic dialysis if
transplantation needs to be deferred because a suitable donor is
not available [117]. Although the course of HCV generally
post-RT appears indolent there are clearly individual patients
with poor outcomes due to HCV acquisition from donor organs as
described by Pereira et al [112]. On the basis of the observation
that reinoculation of chimpanzees with homologous as well as
heterologous strains of HCV causes exacerbations of clinical
hepatitis, transplantation of organs from HCV seropositive do-
nors to seropositive recipients may also pose a risk to the recipient
[118]. The impact of HCV viremia in the absence of biochemical
evidence of liver injury on patient survival also remains uncertain
[119]. In summary, increasingly the literature suggests that use of
the HCV-positive donor frequently results in HCV transmission
and that at least some patients suffer adverse outcomes as a result.
Even though HCV typically takes many years to produce hepatic
decompensation the occurrence of subfulminant liver failure in
individual recipients as reported by Pereira et al [112] and others
(G. Danovitch, personal communication) is a cogent argument
against the use of anti-HCV seropositive donors on ethical
grounds.
Table 3. Comparison of HCV and HBV infection
Factor Results Comments
Transmission HBV spread very Necessity for isolation










Severity of liver HBV implicated Biopsy provides








form of chronic viral
hepatitis
Risk of progression Clinically Long natural history










Abbreviations are: HCV, hepatitis C virus; HBV, hepatitis B virus; RT,
renal transplantation.
Role of antiviral therapy in recipients of renal transplants
Alpha-interferon has well documented efficacy in the treatment
of chronic hepatitis B [70] and C [120] in immunocompetent
hosts. Unfortunately, detailed information is not available about a
possible role for alpha-interferon in the treatment of chronic viral
hepatitis in RT recipients. However, when alpha-interferon was
used in high doses as prophylaxis against cytomegalovirus and
herpes virus infections in RT recipients, a marked increase in the
frequency of acute graft rejection resulted [121], although lower
doses of interferon had previously been used without increased
rates of graft rejection in RT recipients [122]. Alpha-interferon in
the usual dose used to treat chronic HCV was well tolerated and
efficacious in a group of HD patients [1231. However, in a group
of 13 RT recipients treated with standard doses of interferon-
alpha for chronic viral hepatitis, two patients experienced deteri-
oration of graft function. In one ease this was felt to be due to
active chronic rejection and in the other acute tubular necrosis.
Overall, serum aminotransferases decreased during therapy but
the response was not sustained once therapy was stopped and side
effects were common [124]. Thus, at present use of alpha-
interferon is probably best reserved for controlled trials of anti-
viral therapy in RT recipients with chronic viral hepatitis. It is
hoped that, in the future, newer anti-viral agents without the
potent immunomodulating effects of interferon will be available.
The apparent inability of the host to mount neutralizing antibod-
ies suggests that development of an effective HCV will be difficult
[118].
Summary
Effective control measures to reduce the spread of HBV in
dialysis units have had a major beneficial impact on the manage-
ment of patients with chronic renal failure (Table 3). The exact
impact of chronic HBV infection on graft and patient survival
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following RT remains unclear, and the outcome may depend in
great part on the severity of the pre-RT liver disease. RT should
only be offered to HBV-infected patients after careful consider-
ation of all the pertinent data, including results of liver biopsy.
Advances in HBV vaccination may further decrease the risk of
infection in patients on HD. Our understanding of HCV is
evolving rapidly, but the question of the risk of transmission of
HCV within dialysis units is still unsettled and thus recommenda-
tions about isolation of HCV-infected patients are not possible.
Although RT does not appear to be deleterious in many HCV-
infected patients, histologic and clinical evidence of severe liver
disease should also prompt caution in offering RT. Longer term
studies are required to assess the ultimate effect of RT in patients
with HCV. Clearly, subjective improvement of quality of life
associated with successful RT compared to chronic dialysis should
not be withheld lightly. Pending further experience, use of organs
from anti-HCV-positive donors in non-emergent situations is best
avoided. The role of antiviral agents in RT recipients with chronic
viral hepatitis also remains to be defined. Improved supportive
care of patients with chronic renal disease, including erythropoi-
etin therapy, as well as improved tests for anti-HCV screening of
donor blood will help to further diminish exposure to HCV in HD
units.
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